Christopher Williams, NP
Family · Groves, TXNPI 1295158368
Payments from drug & device makers
Across 443 payments — averaging $22.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Biohaven Pharmaceutical Holding Company Ltd.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Alkermes, Inc.$977
- Sunovion Pharmaceuticals Inc.$694
- Lundbeck LLC$694
- plus $4K from 18 others
What the payments were for
- Consulting fees$8008%
- Travel & lodging$3043%
- Food & beverage$8,84688%
- Education$581%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 87 | $1,445 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $1,270 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 55 | $1,243 |
| Alkermes, Inc. | 48 | $977 |
| Sunovion Pharmaceuticals Inc. | 39 | $694 |
| Lundbeck LLC | 31 | $694 |
| Corium, LLC | 26 | $526 |
| Otsuka America Pharmaceutical, Inc. | 23 | $505 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $492 |
| Teva Pharmaceuticals USA, Inc. | 16 | $332 |
| Axsome Therapeutics, Inc. | 10 | $249 |
| Vanda Pharmaceuticals Inc. | 12 | $223 |
| Tris Pharma Inc | 12 | $209 |
| Neurocrine Biosciences, Inc. | 9 | $209 |
| Ironshore Pharmaceuticals Inc. | 10 | $189 |
| Inari Medical, Inc. | 1 | $180 |
| Johnson & Johnson | 9 | $161 |
| Idorsia Pharmaceuticals US Inc | 6 | $100 |
| Merck | 6 | $82 |
| Neos Therapeutics, LP | 3 | $61 |
| Bausch Health US, LLC | 3 | $60 |
| Almatica Pharma LLC | 2 | $57 |
| Supernus Pharmaceuticals, Inc. | 2 | $34 |
| Noven Therapeutics, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,008 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 25 | $35,103 |
| RexultiBrexpiprazole | 15 | $17,750 |
| TrintellixVortioxetine Hydrobromide | 16 | $9,216 |
| EntrestoSacubitril/Valsartan | 15 | $3,882 |
| Bupropion XlBupropion Hcl | 76 | $1,939 |
| Escitalopram Oxalate | 127 | $1,774 |
| Duloxetine Hcl | 64 | $1,652 |
| Aripiprazole | 64 | $1,387 |
| Sertraline Hcl | 46 | $1,203 |
| Trazodone Hcl | 106 | $1,032 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 26 | $890 |
| Ziprasidone Hcl | 17 | $809 |
| Quetiapine Fumarate | 41 | $720 |
| Memantine Hcl | 14 | $704 |
| Buspirone Hcl | 62 | $650 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,445 | $35,10325 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $505 | $17,75015 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $492 | $9,21616 claims |
| Almatica Pharma LLCSertraline Hcl | $57 | $1,20346 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in Groves
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.